RxDoctor Payments Data

Sachin Pai

Medical Oncology · Mobile, ALNPI 1942512637

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,900 of the $7,594 with a category attached, or 90.9%. AstraZeneca accounts for 93.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $7,096 and has fallen 99.5% since, to $35 in 2025.

$7,594in general payments, 2019–2025

Across 26 payments — averaging $292.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Astellas Pharma US Inc$252
  • AbbVie$58
  • Eisai Inc.$47
  • Pfizer$25
  • Novartis$22
  • plus $91 from 6 others
$2,092,957in research payments, 2019–2025

Across 680 payments — averaging $3077.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$1.6M
  • Incyte Corporation$522K

What the payments were for

  • Consulting fees$6,90091%
  • Food & beverage$5427%
  • Education$1522%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,594 in reported general payments places this provider in the 55th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama

Other medical oncology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →